Patients receiving Abilify Maintena: 960mg once every 2 months; may administer in place of next scheduled inj; reduce to 720mg once every 2 months if adverse reactions occur. Dose adjustments for ...
A drug-device combination, Abilify MyCite was approved by the US regulator for schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and as an add-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback